These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37270427)

  • 1. High-dose tramadol conversion to buprenorphine-naloxone.
    Kirk JK; Boyd CT; Cassidy-Vu L; McRae LP; Strickland HE; Fagan EB
    J Opioid Manag; 2023; 19(2):187-190. PubMed ID: 37270427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The problem of pain: Additive analgesic effect of tramadol and buprenorphine in a patient with opioid use disorder.
    Montalvo C; Genovese N; Renner J
    Subst Abus; 2019; 40(2):136-139. PubMed ID: 30835647
    [No Abstract]   [Full Text] [Related]  

  • 3. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
    Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
    J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful Buprenorphine/Naloxone Low-dose Induction in Pregnancy: A Case Report.
    Coish R; Hardial J
    J Addict Med; 2023 Jan-Feb 01; 17(1):114-116. PubMed ID: 35916416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose buprenorphine for treatment of high potency opioid use disorder.
    Danilewitz M; McLean M
    Drug Alcohol Rev; 2020 Feb; 39(2):135-137. PubMed ID: 31769109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating opioid use disorder with rapid micro induction technique of sublingual buprenorphine/naloxone in an outpatient setting-a case report.
    Martell JP; Konakanchi JS; Sethi R
    J Addict Dis; 2022; 40(3):439-443. PubMed ID: 35072589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term buprenorphine treatment for kratom use disorder: A case series.
    Broyan VR; Brar JK; Allgaier Student T; Allgaier JT
    Subst Abus; 2022; 43(1):763-766. PubMed ID: 35112990
    [No Abstract]   [Full Text] [Related]  

  • 8. Tramadol dependence: treatment with buprenorphine/naloxone.
    Ritvo JI; Koonce R; Thurstone CC; Causey HL
    Am J Addict; 2007; 16(1):67-8. PubMed ID: 17364425
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful rotation from long-acting full agonist opioids to sublingual buprenorphine/naloxone using a microdosing approach.
    Vytialingam RC; Schug SA; O'Regan R
    J Opioid Manag; 2021; 17(7):159-166. PubMed ID: 34520037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case of buprenorphine-associated central sleep apnea resolving with dose reduction.
    Tchikrizov V; Richert AC; Bhardwaj SB
    J Opioid Manag; 2022; 18(4):391-394. PubMed ID: 36052936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing A Rapid Transfer from Opioid Full Agonist to Buprenorphine: "Ultrarapid Micro-Dosing" Proof of Concept.
    Azar P; Mathew N; Mahal D; Wong JSH; Westenberg JN; Schütz CG; Greenwald MK
    J Psychoactive Drugs; 2023; 55(1):94-101. PubMed ID: 35152847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flexible Buprenorphine/Naloxone Treatment Models: Safe and Effective in Reducing Opioid Use Among Persons With Prescription Opioid Use Disorder.
    Saunders EC
    Am J Psychiatry; 2022 Oct; 179(10):699-701. PubMed ID: 36181331
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of Kratom Withdrawal and Dependence With Buprenorphine/Naloxone: A Case Series and Systematic Literature Review.
    Weiss ST; Douglas HE
    J Addict Med; 2021 Apr; 15(2):167-172. PubMed ID: 32858563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.
    Cottrill CB; Matson SC
    Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312
    [No Abstract]   [Full Text] [Related]  

  • 15. The association of Medicare Part D prior authorization for buprenorphine-naloxone with adherence to opioid use disorder treatment guidelines in the United States.
    Parish WJ; Mark TL; Zarkin GA; Weber E
    Addiction; 2022 Jan; 117(1):141-150. PubMed ID: 34033177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
    Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
    J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
    [No Abstract]   [Full Text] [Related]  

  • 17. Management of opioid painkiller dependence in primary care: ongoing recovery with buprenorphine/naloxone.
    Hard B
    BMJ Case Rep; 2014 Nov; 2014():. PubMed ID: 25432908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effectiveness and tolerance of tramadol in cancer pain. A comparative study with respect to buprenorphine].
    Bono AV; Cuffari S
    Drugs; 1997; 53 Suppl 2():40-9. PubMed ID: 9190324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Case Report: Rapid Micro-Induction of Buprenorphine/Naloxone to Administer Buprenorphine Extended-Release in an Adolescent With Severe Opioid Use Disorder.
    Azar P; Wong JSH; Jassemi S; Moore E; Vo DX; Nikoo M; Young S
    Am J Addict; 2020 Nov; 29(6):531-535. PubMed ID: 32346944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.